Caprock Group’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.62M | Buy |
5,519
+2,175
| +65% | +$715K | 0.04% | 405 |
|
|
2025
Q4 | $1.17M | Sell |
3,344
-1,796
| -35% | -$607K | 0.02% | 563 |
|
|
2025
Q3 | $1.64M | Buy |
+5,140
| New | +$1.6M | 0.04% | 413 |
|
|
2025
Q1 | $2.78M | Buy |
6,380
+989
| +18% | +$397K | 0.08% | 207 |
|
|
2024
Q4 | $1.99M | Buy |
+5,391
| New | +$2.26M | 0.07% | 261 |
|
|
2024
Q3 | – | Sell |
-6,318
| Closed | -$3.42M | – | 926 |
|
|
2024
Q2 | $3.42M | Buy |
6,318
+2,108
| +50% | +$1.11M | 0.14% | 118 |
|
|
2024
Q1 | $2.18M | Sell |
4,210
-150
| -3% | -$74.6K | 0.13% | 116 |
|
|
2023
Q4 | $2.06M | Sell |
4,360
-39
| -0.9% | -$18K | 0.13% | 126 |
|
|
2023
Q3 | $1.92M | Buy |
4,399
+65
| +1% | +$29.5K | 0.14% | 107 |
|
|
2023
Q2 | $1.93M | Sell |
4,334
-24
| -0.6% | -$11.1K | 0.14% | 113 |
|
|
2023
Q1 | $2M | Buy |
4,358
+284
| +7% | +$135K | 0.16% | 106 |
|
|
2022
Q4 | $2.09M | Buy |
4,074
+225
| +6% | +$114K | 0.19% | 81 |
|
|
2022
Q3 | $1.75M | Buy |
3,849
+114
| +3% | +$54.5K | 0.17% | 83 |
|
|
2022
Q2 | $1.8M | Buy |
3,735
+233
| +7% | +$115K | 0.18% | 84 |
|
|
2022
Q1 | $1.72M | Buy |
3,502
+451
| +15% | +$206K | 0.16% | 105 |
|
|
2021
Q4 | $1.41M | Buy |
3,051
+255
| +9% | +$107K | 0.12% | 129 |
|
|
2021
Q3 | $1.04M | Buy |
2,796
+41
| +1% | +$15.6K | 0.09% | 149 |
|
|
2021
Q2 | $1.05M | Buy |
2,755
+14
| +0.5% | +$5.35K | 0.1% | 157 |
|
|
2021
Q1 | $984K | Sell |
2,741
-499
| -15% | -$160K | 0.11% | 146 |
|
|
2020
Q4 | $1.04M | Sell |
3,240
-173
| -5% | -$53.1K | 0.12% | 137 |
|
|
2020
Q3 | $917K | Buy |
3,413
+254
| +8% | +$68.3K | 0.13% | 128 |
|
|
2020
Q2 | $831K | Buy |
3,159
+363
| +13% | +$96.8K | 0.12% | 134 |
|
|
2020
Q1 | $635K | Buy |
2,796
+80
| +3% | +$21.8K | 0.12% | 129 |
|
|
2019
Q4 | $820K | Buy |
2,716
+353
| +15% | +$97.1K | 0.15% | 115 |
|
|
2019
Q3 | $567K | Buy |
2,363
+193
| +9% | +$52.9K | 0.11% | 140 |
|
|
2019
Q2 | $612K | Sell |
2,170
-179
| -8% | -$48.9K | 0.12% | 142 |
|
|
2019
Q1 | $674K | Sell |
2,349
-394
| -14% | -$114K | 0.13% | 138 |
|
|
2018
Q4 | $720K | Buy |
2,743
+141
| +5% | +$38.8K | 0.17% | 115 |
|
|
2018
Q3 | $713K | Sell |
2,602
-2
| -0.1% | -$519 | 0.15% | 128 |
|
|
2018
Q2 | $620K | Sell |
2,604
-25
| -1% | -$5.79K | 0.13% | 144 |
|
|
2018
Q1 | $578K | Sell |
2,629
-1
| -0% | -$235 | 0.12% | 156 |
|
|
2017
Q4 | $631K | Buy |
2,630
+20
| +0.8% | +$4.26K | 0.12% | 165 |
|
|
2017
Q3 | $496K | Sell |
2,610
-100
| -4% | -$19K | 0.1% | 189 |
|
|
2017
Q2 | $510K | Buy |
2,710
+130
| +5% | +$23.4K | 0.11% | 170 |
|
|
2017
Q1 | $427K | Sell |
2,580
-136
| -5% | -$21.6K | 0.1% | 181 |
|
|
2016
Q4 | $390K | Sell |
2,716
-496
| -15% | -$66.4K | 0.1% | 185 |
|
|
2016
Q3 | $402K | Buy |
+3,212
| New | +$415K | 0.09% | 209 |
|
Other funds holding ELV
VCM
VPM
Caprock Group's ELV Position: Q1 2026 in Review
Caprock Group increased its Elevance Health (ELV) stake by 65% in Q1 2026, buying an estimated $715K and bringing the position to 5,519 shares worth $1.62M. The position accounts for 0.04% of the portfolio, ranked #405.
Caprock Group first reported a position in ELV in Q3 2016 and has held it in 37 quarters since. The position peaked at $3.42M in Q2 2024. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- Caprock Group held 5,519 shares of Elevance Health worth $1.62M as of Q1 2026.
- Caprock Group bought 2,175 Elevance Health shares in Q1 2026, an estimated $715K.
- Elevance Health made up 0.04% of Caprock Group's portfolio in Q1 2026, its #405 holding.
- Caprock Group first reported a position in Elevance Health in Q3 2016 and has held it in 37 quarters since.
- Caprock Group's Elevance Health position peaked at $3.42M in Q2 2024.
- 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.